FDA Approves Dako's Genetic Test for Breast Cancer Recurrence | GenomeWeb
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved a genetic test made by Dako Denmark designed to predict if a breast cancer tumor will recur and a patient’s chances of long-term survival, the FDA said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.